UVA registers Phase 1b/2 trial of Verastem's avutometinib/defactinib in pancreatic cancer

This week brought one new trial registration involving Verastem's drug combination in pancreatic cancer.

• A Phase Ib/II study titled "Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma" (NCT07824960, acronym Panc 004) is listed as not yet recruiting, sponsored by the University of Virginia with Verastem, Inc. as collaborator. The trial plans to enroll 31 participants (estimated)¹ and will evaluate whether avutometinib and defactinib are safe for patients with pancreatic ductal adenocarcinoma (PDAC)¹, with the drugs given in combination with mFOLFIRINOX (standard of care chemotherapy) in 28-day cycles for up to 6 cycles¹. The study has two parts, with dose limiting toxicities as the primary outcome in Part A and objective response as the primary outcome in Part B¹, and an estimated primary completion date of 2029-04.